Company · founded 1986
Opexa Therapeutics (United States)
The Woodlands, United States · opexatherapeutics.com/index.php
- Citations, last 5 years
- 3
- Works, last 5 years
- 7
- h-index
- 40
- Scientists listed
- 1
- Grants since 2016
- 7
Grants received
2024–2025 · grant · Standard Grant
SBIR Phase I: AI-driven PROTAC drug discovery - Pioneering non-hormonal therapeutic targets for uterine fibroids and endometriosis
Morgan Stanton · Opexa Therapeutics (United States) · funded by National Science Foundation
2023–2026 · cooperative agreement · U44
Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
Olivia Ruth Asfaha · Opexa Therapeutics (United States) · funded by National Institutes of Health
2023–2026 · cooperative agreement · U44
Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
Olivia Ruth Asfaha · Opexa Therapeutics (United States) · funded by National Institutes of Health
2023–2026 · cooperative agreement · U44
Comparative testing of tatCN19o for neuroprotection in rodent tMCAo
Olivia Ruth Asfaha · Opexa Therapeutics (United States) · funded by National Institutes of Health
2021–2023 · research · R43
Preparing for IND-enabling safety studies for a potent and efficient neuroprotective drug.
Robyn L Goforth · Opexa Therapeutics (United States) · funded by National Institutes of Health
2021–2027 · research · R44
IND-enabling studies for a potent and efficient neuroprotective drug
Robyn L Goforth · Opexa Therapeutics (United States) · funded by National Institutes of Health
2021–2027 · research · R44
IND-enabling studies for a potent and efficient neuroprotective drug
Robyn L Goforth · Opexa Therapeutics (United States) · funded by National Institutes of Health
